menu search

Biogen's alzheimer's drug is the biggest growth catalyst for the stock, says jefferies' yee

Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for ...

July 28, 2023, 3:27 pm

I'm excited for what alzheimer's drugs will do for patients, says ge healthcare ceo peter arduini

GE Healthcare President and CEO Peter Arduini goes one-on-one with 'Mad Money' host Jim Cramer to talk the spinoff from GE and what the past year has ...

July 25, 2023, 8:08 pm

Biogen to cut 1,000 jobs as focus turns to alzheimer's drug leqembi launch

Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat ...

July 25, 2023, 1:35 pm

Biogen layoffs 2023: what to know about the latest biib job cuts

Biogen (NASDAQ: BIIB ) layoffs are on the way as the company seeks further profits with its new alzheimer...

July 25, 2023, 9:35 am

Biogen to cut roughly 11% of workforce

The biotech cited the launch of alzheimer's drug Leqembi as part of its new focus....

July 25, 2023, 9:26 am

Biogen tops second-quarter estimates with alzheimer's drug not yet profitable

Biogen reported second-quarter profits that fell 23% while revenue slid 5%, but the biotech's results still came in ahead of views....

July 25, 2023, 9:24 am

Biogen tops earnings estimates and says it will shift resources to higher value areas

Biogen Inc.'s stock BIIB, +0.09% rose 1.1% premarket Tuesday, after the company swept past earnings estimates for the second quarter and said it will ...

July 25, 2023, 7:36 am

Biogen to cut 1,000 jobs to save costs as alzheimer's drug launch gathers pace

Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a ...

July 25, 2023, 7:05 am

All eyes on biogen's alzheimer's drug, a big potential payday, ahead of earnings

Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its ...

July 24, 2023, 5:46 pm

Mps ii and beyond: implications of denali's promising pipeline

Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific ...

July 23, 2023, 12:51 am

Lilly joins biogen as alzheimer's drugs finally emerge

In trials, Biogen and Eli Lilly have shown that their drugs can slow early-stage decline in the disease. It could be a bonanza for patients—and inve...

July 21, 2023, 8:03 pm

Eisai presents latest analysis of lecanemab’s effect on biomarker changes and subcutaneous dosing at the alzheimer’s association international conference (aaic) 2023

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of ...

July 19, 2023, 11:30 pm

Acumen soars on alzheimer's study

Two years removed from an IPO, Acumen Pharmaceuticals, Inc. NASDAQ: ABOS looks like it made a good decision to go public. Shares of the Charlottesvill...

July 19, 2023, 9:59 am

Acumen announces pricing of upsized $130 million public offering

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage...

July 19, 2023, 2:31 am

Eli lilly's alzheimer's drug slows cognitive decline: study

Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the latest study on the experimental drug, as well as Pfizer's partnership with Flagship...

July 18, 2023, 5:31 pm

Lilly's (lly) donanemab slows alzheimer's disease progression

Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants...

July 18, 2023, 12:50 pm

Biogen, eli lilly likely to split the alzheimer's drug market, analysts say

Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the ...

July 18, 2023, 8:39 am

Acumen: a first in targeting, may lead to improvement for early ad patients

Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market fo...

July 18, 2023, 8:34 am

Biovie updates on its progress and recent findings

BioVie Inc (NASDAQ:BIVI) has issued a letter to shareholders providing an update on its progress and recent findings. The letter highlights the compan...

July 18, 2023, 8:17 am

Acumen pharmaceuticals announces proposed public offering of common stock

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceuti...

July 17, 2023, 8:53 pm


Search within

Pages Search Results: